|Day Low/High||80.34 / 80.67|
|52 Wk Low/High||59.66 / 86.85|
Cramer says Quest Diagnostics has gone up by too much while he likes Cerner for the long term.
Cramer says his game plan is all about earnings, when the fundamentals control the market.
The most recent short interest data has been released for the 09/30/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
These stocks have both short-term gain catalysts and longer-term growth prospects.
Company also introduces molecular Zika testing for serum and paired urine
Annual Drug Testing Index Reveals Fifth Straight Year of Increases in Detection Rate of Amphetamine and Heroin; Marijuana Positivity Increases 47 Percent Since 2013 in Oral Fluid Testing
The most recent short interest data has been released for the 08/31/2016 settlement date, which shows a 855,753 share decrease in total short interest for Quest Diagnostics, Inc. , to 5,618,473, a decrease of 13.22% since 08/15/2016.
Optum, a leading information and technology-enabled health services business, and Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced they will partner to help make...
Where some see danger and upheaval, investors see opportunity. And the harrowing Zika virus is no different. Investors are jumping into stocks focused on detecting or wiping out the virus.
New Service Centers Offer Retail Convenience, With or Without a Doctor's Order
eCCF dramatically improves efficiency and time savings in workplace drug testing
These stocks have both short-term gain catalysts and longer-term growth potential.
First digital testing technology from diagnostics leader is designed to help primary care physicians and ACOs improve the detection and monitoring of patients with dementias such as Alzheimer's disease
World leaders in consumer genomics and diagnostic information services team up
Stocks with insider trader activity include TUP, DGX and EXPO
Healthcare analytics technology from Quest Diagnostics and Inovalon supports adoption of value-based care
Study Finds Sharp Increase in Patients Who Combine Prescribed Medications with Other Drugs; Two in Three Users of Heroin Take it with Benzodiazepines, a Potentially Lethal Combination
Largest percentage of children with very high blood lead levels concentrated in six regions, including in New York, Pennsylvania and Ohio
HIGHLIGHTS FROM THE QUEST DIAGNOSTICS/INOVALON STUDY INCLUDE: